tt-00434
Small moleculeexperimental
Clinical trial activity
1 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Jul 12, 2021 (NCT04830501)
Timeline
2020s
- Jan 1, 2021
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Fibroblast growth factor receptor 3ANTAGONIST
FGFR3 antagonist
- Fibroblast growth factor receptor 2ANTAGONIST
FGFR2 antagonist
- Fibroblast growth factor receptor 1ANTAGONIST
FGFR1 antagonist
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04830501 | Phase 1 | Jul 12, 2021 | Government of Taiwan, National Cheng Kung University, Taipei Medical University, TransThera Biosciences Co., Ltd |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Government of Taiwan | Government | 1 | 0 | 1 | 2021 |
| National Cheng Kung University | Academic/Hospital | 1 | 0 | 1 | 2021 |
| Taipei Medical University | Academic/Hospital | 1 | 0 | 1 | 2021 |
| TransThera Biosciences Co., Ltd | For profit | 1 | 1 | 1 | 2021 |
4 organizations
Page 1 / 1